396 related articles for article (PubMed ID: 30900516)
21. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
[TBL] [Abstract][Full Text] [Related]
22. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4].
Dietlein M; Eschner W; Grünwald F; Lassmann M; Verburg FA; Luster M
Nuklearmedizin; 2016 Jun; 55(3):77-89. PubMed ID: 27350004
[TBL] [Abstract][Full Text] [Related]
23. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm.
Roman BR; Feingold JH; Patel SG; Shaha AR; Shah JP; Tuttle RM; Epstein AJ
Thyroid; 2014 Oct; 24(10):1549-50. PubMed ID: 25065817
[No Abstract] [Full Text] [Related]
24. Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer.
Boucher A; Ezzat S; Hotte S; Rachinsky I; Rajaraman M; Ruether D; Wiseman SM; Brierley J; Ho C; Krzyzanowska M; Lamond N; Massicotte MH; Joseph S; Herscovitch K; Sikora L; Winquist E
Oral Oncol; 2021 Oct; 121():105477. PubMed ID: 34388408
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?
Verburg FA; Luster M; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):183-184. PubMed ID: 27726016
[No Abstract] [Full Text] [Related]
26. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
[TBL] [Abstract][Full Text] [Related]
27. Differentiated thyroid carcinoma referred for radioiodine therapy.
Al-Balawi IA; Meir HM; Yousef MK; Nayel HA; Al-Mobarak MF
Saudi Med J; 2001 Jun; 22(6):497-503. PubMed ID: 11426239
[TBL] [Abstract][Full Text] [Related]
28. [The basis for radioiodine therapy in differentiated thyroid cancer].
Haldemann AR
Ther Umsch; 1999 Jul; 56(7):403-7. PubMed ID: 10434780
[TBL] [Abstract][Full Text] [Related]
29. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
30. Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
Forleo R; Fralassi N; Maino F; Capezzone M; Brilli L; Pilli T; Cantara S; Castagna MG
J Endocrinol Invest; 2021 Jan; 44(1):139-144. PubMed ID: 32388842
[TBL] [Abstract][Full Text] [Related]
31. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
32. Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.
Campennì A; Barbaro D; Guzzo M; Capoccetti F; Giovanella L
Endocrine; 2020 Nov; 70(2):280-291. PubMed ID: 32772339
[TBL] [Abstract][Full Text] [Related]
33. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
34. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.
Castagna MG; Cantara S; Pacini F
J Endocrinol Invest; 2016 Oct; 39(10):1087-94. PubMed ID: 27350556
[TBL] [Abstract][Full Text] [Related]
35. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
36. Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.
Schmidt M; Bartenstein P; Bucerius J; Dietlein M; Drzezga A; Herrmann K; Lapa C; Lorenz K; Musholt TJ; Nagarajah J; Reiners C; Sahlmann CO; Kreissl MC
Nuklearmedizin; 2022 Apr; 61(2):87-96. PubMed ID: 35299276
[TBL] [Abstract][Full Text] [Related]
37. Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration.
Sun YQ; Sun D; Zhang X; Zhang YQ; Lin YS
Front Endocrinol (Lausanne); 2022; 13():994288. PubMed ID: 36531486
[TBL] [Abstract][Full Text] [Related]
38. Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer.
Jacobs D; Breen CT; Pucar D; Holt EH; Judson BL; Mehra S
Thyroid; 2021 Feb; 31(2):272-279. PubMed ID: 32811347
[No Abstract] [Full Text] [Related]
39. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
